This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was based on the analysis of a retrospective cross-sectional diagnostic study, where FNAB, FS and the reference test were performed on all patients. The study was conducted in a single centre. The patients were followed until the diagnosis was made. The reference test was definitive histological analysis of between 4 and 10 serial sections. The pathologist who reported the FS was blinded to the results of the other test. The results of FNAB were classified as benign, malignant or suspicious. The indications for operation included a cytological diagnosis of malignancy or of suspected malignancy, so suspected malignancies were grouped together with malignancies in the analysis. The results of FS were classified as benign, malignant or deferred (inconclusive). For statistical analysis, the inconclusive results were classified as false negatives.
Analysis of effectiveness
All patients included in the study sample were accounted for in the analysis. The health outcomes used in the analysis were the sensitivity, specificity, overall accuracy, positive predictive value (PPV) and negative predictive value (NPV).
Effectiveness results
For FNAB, of the 206 patients, 79 were benign, 113 suspicious and 14 malignant.
For FS, of the 206 patients, 165 were benign, 8 deferred and 33 malignant.
The sensitivity values were 88% for FNAB and 80% for FS.
The specificity values were 45% for FNAB and 99% for FS.
The accuracy values were 53% for FNAB and 96% for FS.
The PPV was 28% for FNAB and 97% for FS.
The NPV was 94% for FNAB and 95% for FS.
Clinical conclusions
The main result of the effectiveness analysis was that FNAB was associated with higher sensitivity than FS. However, FS had much higher specificity.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used. A cost-consequences analysis was therefore conducted.
Direct costs
The cost/resource boundary was that of the third-party payer. The health service costs included in the economic evaluation were thyroidectomy, FS and FNAB. Discounting was not relevant since the costs were incurred over a short period of time. The unit costs were reported separately from the quantities of resources used. The costs were estimated on the basis of regional refunding fees to the study hospital. Resource consumption was obtained from the actual consumption of the patients included in the effectiveness study from January 1995 to December 2000. The hypothetical costs of performing either no FS or FS in all patients were calculated. No price year was reported.
